Aprea Therapeutics Inc. (NASDAQ: APRE) presented updated Phase 1 data for its WEE1 inhibitor APR-1051 at the American Society of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE